NEW HAVEN, Conn., Jan. 31, 2020 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced
the appointment of Michael Heffernan
to its Board of Directors ("Board").
Mr. Heffernan is a seasoned biopharmaceutical leader with over
25 years of commercial experience. Mr. Heffernan is a pharmacist
and began his career at Eli Lilly and Company where he served in
numerous sales and marketing roles. Mr. Heffernan most recently
served as Founder and CEO of Collegium (Nasdaq: COLL), and remains
Chairman of its Board of Directors. Mr. Heffernan has been an
advisor, investor and board member in a number of biopharmaceutical
and healthcare services companies. His recent board memberships
include: TyRx (sold to Medtronic), PreCision Dermatology (sold to
Valeant), Ocata Therapeutics (sold to Astellas), and Veloxis (Sold
to Asahi Kasei). He is also currently Chairman of the Board of
Carisma Therapeutics and of Indalo Therapeutics and is a member of
the board of Akebia Therapeutics (AKBA) and Trevi Therapeutics
(TRVI).
Vlad Coric, M.D., CEO of
Biohaven, commented, "As we prepare for commercialization of our
lead asset, we are excited to welcome Mike as a key member of our
Board effective January 31,
2020. Mike is an experienced commercial leader and
entrepreneur who started and built his own company through
commercialization. He has cross-functional executive experience in
commercial operations, global sales and marketing, clinical
development, regulatory affairs, and business development within
the biopharmaceutical industry. Mike will be a tremendous asset to
us in this first year of our anticipated commercial launch."
Michael Heffernan stated,
"Biohaven has had incredible progress in its portfolio development
since it became a public company and is now close to
commercializing its first asset. I am excited to be joining at this
pivotal stage as the company transforms from a development to a
commercial organization. I look forward to contributing to my
commercial experience into Biohaven's future success and working
closely with Vlad and the rest of the Board," commented Mr.
Heffernan.
The company also announced that Eric
Aguiar and Bob Repella were
resigning from the Board, effective today. Mr. Repella will
continue his relationship with Biohaven, as a consultant. Dr.
Aguiar and Mr. Repella played important strategic and development
roles in guiding Biohaven to its first NDA submission and
preparation for commercial launch.
Declan Doogan, M.D., Chairman of
Biohaven's Board of Directors, added, "As Biohaven continues its
evolution to a commercial organization, we are excited to welcome
Mike to Biohaven's Board of Directors. We are immensely grateful
for the prior service of Eric and Bob that guided the company to
increased shareholder value and growth in our pipeline."
About Biohaven
Biohaven is a clinical-stage
biopharmaceutical company with a portfolio of innovative,
late-stage product candidates targeting neurological diseases,
including rare disorders. Biohaven has combined internal
development and research with intellectual property licensed from
companies and institutions including Bristol-Myers Squibb Company,
AstraZeneca, Yale University, Catalent,
Rutgers, and ALS Biopharma LLC.
Currently, Biohaven's lead development programs include multiple
compounds across its CGRP receptor antagonist, glutamate
modulation, and myeloperoxidase inhibitor platforms. Biohaven's
common shares are listed on the New York Stock Exchange and traded
under the ticker symbol BHVN. More information about Biohaven is
available at www.biohavenpharma.com.
Forward-Looking Statement
This news release may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of the Company's management. All
statements, other than statements of historical facts, included in
this press release, including the Company's expectations for future
growth, commercialization and pipeline development, are
forward-looking statements. You should not place undue reliance on
the Company's forward-looking statements. Various important factors
could cause actual results or events to differ materially from
those that may be expressed or implied by our forward-looking
statements. Important factors to be considered in connection with
forward-looking statements are described in the "Risk Factors"
section of the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on February 28, 2019 and the Company's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2019, filed with the Securities and
Exchange Commission on November 1,
2019. The forward-looking statements are made as of this
date and the Company does not undertake any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
For further information, contact Dr. Vlad Coric, the Chief
Executive Officer at Vlad.Coric@biohavenpharma.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-appoints-michael-heffernan-to-board-of-directors-300997125.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.